CLINICAL NEUROPHARMACOLOGY

Scope & Guideline

Elevating Standards in Neurological Pharmacological Research

Introduction

Welcome to your portal for understanding CLINICAL NEUROPHARMACOLOGY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0362-5664
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1982 to 2024
AbbreviationCLIN NEUROPHARMACOL / Clin. Neuropharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'Clinical Neuropharmacology' focuses on advancing the understanding and treatment of neurological and psychiatric disorders through pharmacological interventions. It encompasses a wide range of studies, including clinical trials, observational studies, and reviews, aimed at improving patient outcomes in neuropsychiatric conditions.
  1. Clinical Efficacy of Pharmacological Treatments:
    The journal emphasizes research that evaluates the clinical effectiveness and safety of various pharmacological treatments for neurological and psychiatric disorders, highlighting evidence from randomized controlled trials and meta-analyses.
  2. Neuropharmacogenetics and Personalized Medicine:
    There is a consistent focus on the genetic factors that influence drug response in patients with neurological conditions, aiming to tailor treatments based on individual genetic profiles.
  3. Innovative Therapeutics and Emerging Drugs:
    The journal publishes studies on new and emerging therapeutic agents, including their mechanisms of action, efficacy, and safety profiles, thereby contributing to the development of novel treatment strategies.
  4. Neurobiology of Mental Health Disorders:
    Research exploring the neurobiological underpinnings of psychiatric disorders is a core area, with studies examining the role of neurotransmitters, neuroinflammation, and neuroplasticity in mental health.
  5. Real-World Evidence and Clinical Practice:
    The journal values real-world studies that assess treatment outcomes across diverse populations, providing insights into the practical implications of pharmacological interventions in everyday clinical settings.
Recent publications in 'Clinical Neuropharmacology' indicate several emerging themes and trends that are gaining traction within the field. These reflect the evolving landscape of neuropharmacology and the increasing complexity of treatment approaches.
  1. Combination Therapies and Adjunctive Treatments:
    There is a growing interest in studies that explore the efficacy of combination therapies, particularly in treatment-resistant cases, highlighting the need for multifaceted approaches in managing complex neuropsychiatric disorders.
  2. Neuroinflammation and Its Role in Neurological Disorders:
    Research examining the role of neuroinflammation in various neurological and psychiatric conditions is on the rise, indicating an increasing recognition of its impact on disease progression and treatment outcomes.
  3. Use of Biomarkers in Treatment Response:
    The exploration of biomarkers for predicting treatment response and monitoring therapeutic efficacy is emerging as a significant trend, reflecting a shift towards personalized medicine in neuropharmacology.
  4. Pediatric Neuropharmacology:
    There is an increasing focus on the pharmacological management of neurological disorders in pediatric populations, addressing the unique challenges and considerations in treating children and adolescents.
  5. Integrative and Alternative Medicine Approaches:
    Studies investigating the integration of alternative and complementary therapies with conventional pharmacological treatments are becoming more prevalent, indicating a broader perspective on patient care.

Declining or Waning

While 'Clinical Neuropharmacology' continues to thrive in several areas, some themes have shown a decline in focus over recent years. This may reflect shifting research priorities or a saturation of literature in these domains.
  1. Traditional Psychiatric Medications:
    There has been a noticeable decrease in studies focusing on traditional psychiatric medications such as older antidepressants and antipsychotics, as newer agents and treatment strategies gain prominence.
  2. Single-Agent Studies:
    Research focusing solely on the efficacy of single-agent pharmacotherapy is less prevalent, with a shift towards combination therapies and multi-modal approaches to treatment.
  3. Case Reports of Rare Adverse Effects:
    The frequency of case reports detailing rare adverse effects of medications has declined, possibly due to a broader focus on systematic reviews and larger cohort studies.

Similar Journals

Therapeutic Advances in Chronic Disease

Innovative insights to transform chronic disease care.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6223Frequency: 1 issue/year

Therapeutic Advances in Chronic Disease is a distinguished open-access journal published by SAGE Publications Ltd, with a focus on innovative research and clinical practices addressing chronic diseases—a field increasingly relevant in today's healthcare landscape. Since its inception in 2010, the journal has committed itself to disseminating high-quality research that informs both theory and practice. With an impressive impact factor and ranked Q1 in Medicine (miscellaneous) in 2023, this journal boasts recognition as one of the top-tier publications in the medical community, placing it in the 79th percentile among its peers. Accessible since 2019, it aims to bridge the gap between cutting-edge research and its application in improving patient outcomes, inviting contributions from researchers, clinicians, and health professionals. The journal's comprehensive scope encompasses various aspects of chronic disease management, making it an invaluable resource for those seeking to advance their understanding of this critical field.

RESTORATIVE NEUROLOGY AND NEUROSCIENCE

Driving Discovery: Elevating the Standards of Neurological Care
Publisher: IOS PRESSISSN: 0922-6028Frequency: 6 issues/year

RESTORATIVE NEUROLOGY AND NEUROSCIENCE, published by IOS PRESS, is a premier journal dedicated to advancing the fields of neurology and neuroscience. Since its inception in 1989, this journal has played a crucial role in disseminating cutting-edge research findings and innovative therapeutic approaches that aim to restore neurological function and improve patient outcomes. With a focus on developmental neuroscience and clinical neurology, the journal holds a 2023 Scopus ranking of #129 out of 400 in clinical neurology, and #15 out of 37 in developmental neuroscience, reflecting its significant influence in these domains. Although it operates on a non-open access model, RESTORATIVE NEUROLOGY AND NEUROSCIENCE offers valuable insights for researchers, healthcare professionals, and students seeking to deepen their understanding of neural restoration mechanisms and therapeutic strategies. Located in Amsterdam, Netherlands, the journal continues to foster scholarly dialogue and innovation, contributing to the global advancement of neuroscience and neurology.

Expert Review of Clinical Pharmacology

Innovating patient outcomes with cutting-edge pharmacology research.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Exploring the future of drug therapy and pharmacokinetics.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Contemporary Clinical Trials Communications

Empowering Innovations in Clinical Trials Communication
Publisher: ELSEVIER INCISSN: Frequency:

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

EXPERT OPINION ON EMERGING DRUGS

Transforming insights into groundbreaking drug developments.
Publisher: TAYLOR & FRANCIS LTDISSN: 1472-8214Frequency: 4 issues/year

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.

NATURE REVIEWS DRUG DISCOVERY

Uncovering breakthroughs in drug discovery.
Publisher: NATURE PORTFOLIOISSN: 1474-1776Frequency: 12 issues/year

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

Expert Review of Neurotherapeutics

Fostering Excellence in Neurotherapeutic Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1473-7175Frequency: 12 issues/year

Expert Review of Neurotherapeutics is an esteemed journal published by Taylor & Francis Ltd, focusing on the rapidly evolving field of neurotherapeutics. With an ISSN of 1473-7175 and an E-ISSN of 1744-8360, this publication aims to bridge the gap between clinical and preclinical research, providing a platform for innovative therapeutic strategies in neurology and neuroscience. The journal boasts impressive impact factor rankings, categorized as Q2 in both clinical neurology and miscellaneous neuroscience, and Q1 in medical pharmacology for 2023. Its reputable placement in Scopus rankings, including Rank #82/400 in clinical neurology, underscores its significance within the medical research community. Spanning from 2001 to 2024, the journal publishes critical reviews and original research articles aimed at enhancing understanding and treatment in neurological disorders. Although it currently does not offer open access, articles published in the journal are crucial for researchers, healthcare professionals, and students seeking to stay at the forefront of advancements in neurotherapeutics. With its strong emphasis on rigorous peer-reviewed content, Expert Review of Neurotherapeutics continues to be a vital resource for those dedicated to improving patient outcomes in the realm of neurology.

Current Neuropharmacology

Unraveling the complexities of neuropharmacology.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-159XFrequency: 8 issues/year

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

NEUROLOGY

Shaping the future of neurology through rigorous research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0028-3878Frequency: 48 issues/year

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.